Spyre Therapeutics (SYRE) Cash from Investing Activities (2015 - 2026)

Spyre Therapeutics has reported Cash from Investing Activities for 12 years, with the latest figure at $56.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 92855.74% year-over-year to $56.6 million; the trailing twelve-month figure through Mar 2026 stood at -$86.8 million (up 65.04% YoY), and the FY2025 full-year result was -$143.5 million, up 59.39% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $56.6 million, up from -$247.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $79.0 million in Q2 2025, with the low at -$247.4 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$28.9 million across 5 years, with a median of $6.8 million in 2023.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 1882.81% — and 2026, when it soared 92855.74%.
• Spyre Therapeutics' Cash from Investing Activities stood at $14.0 million in 2022, then tumbled by 351.94% to -$35.3 million in 2023, then tumbled by 383.51% to -$170.5 million in 2024, then tumbled by 45.07% to -$247.4 million in 2025, then soared by 122.87% to $56.6 million in 2026.
• The last three Cash from Investing Activities figures came in at $56.6 million (Q1 2026), -$247.4 million (Q4 2025), and $25.0 million (Q3 2025), per Business Quant data.